3,202 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Bought by Isthmus Partners LLC

Isthmus Partners LLC acquired a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,202 shares of the specialty pharmaceutical company’s stock, valued at approximately $357,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Versant Capital Management Inc lifted its position in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 269 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in Jazz Pharmaceuticals in the second quarter valued at about $29,000. EverSource Wealth Advisors LLC raised its position in Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after purchasing an additional 97 shares during the last quarter. GAMMA Investing LLC raised its position in Jazz Pharmaceuticals by 65.5% in the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares during the last quarter. Finally, Gladius Capital Management LP bought a new position in Jazz Pharmaceuticals in the second quarter valued at about $33,000. 89.14% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

JAZZ has been the subject of several research reports. Piper Sandler reiterated an “overweight” rating and issued a $163.00 target price (down from $166.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, November 21st. JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. Royal Bank of Canada increased their target price on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, October 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $207.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, November 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Three analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $175.33.

Jazz Pharmaceuticals Trading Down 0.9 %

NASDAQ JAZZ opened at $121.59 on Friday. The business has a 50 day simple moving average of $114.87 and a 200 day simple moving average of $111.12. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $134.17. The stock has a market capitalization of $7.35 billion, a P/E ratio of 17.13, a P/E/G ratio of 1.03 and a beta of 0.57. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares in the company, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. The trade was a 8.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,110 shares of company stock valued at $720,160 over the last 90 days. Company insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.